How have ALZN and ENLV total returns compared?

Over the past 5 years, ALZN delivered -79.14% and ENLV delivered -69.81% annualized total return. Past performance doesn't predict future results.

Alzamend Neuro Inc (ALZN) vs Enlivex Therapeutics Ltd. (ENLV)

A side-by-side comparison of Alzamend Neuro Inc and Enlivex Therapeutics Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ALZN

Alzamend Neuro Inc

$5M

$1.41HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

ENLV

Enlivex Therapeutics Ltd.

$6M

$0.36HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ALZN vs ENLV

growth of $100 · dividends reinvested · last 5y

ALZN -100.0% (-84.9%/yr)ENLV -99.7% (-69.8%/yr)ENLV compounded faster over this window

Log scale — wide-divergence pair

ALZN ENLV

ALZN vs ENLV: by the numbers

•ENLV is the larger company ($6M vs $5M market cap).

Metrics side by side

Valuation

Metric	ALZN	ENLV
P/E ratio	N/A	0.00
P/B ratio	0.92	0.00

Profitability

Metric	ALZN	ENLV
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROE	-156.77%	105.35%
ROIC	-156.69%	-0.32%

Growth (annualized)

Metric	ALZN	ENLV
Total return CAGR (5Y)	-79.14%	-69.81%

Frequently asked

How have ALZN and ENLV total returns compared?: Over the past 5 years, ALZN delivered -79.14% and ENLV delivered -69.81% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ALZN analysis Full ENLV analysis Interactive comparison tool

Dig into the metrics

Alzamend Neuro ROE Enlivex Therapeutics ROE Alzamend Neuro operating margin Enlivex Therapeutics operating margin Alzamend Neuro revenue growth Enlivex Therapeutics revenue growth Alzamend Neuro free cash flow Enlivex Therapeutics free cash flow

Alzamend Neuro & Enlivex Therapeutics appear in these rankings

Highest ROE Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.